Skip to main content
SpringerLink
Log in

SCLC – The forgotten entity

  • Short Review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

As interest in biomarkers, staging and treatment of NSCLC has dramatically increased in the past years, the opposite is true for SCLC. The number of abstracts dealing with SCLC presented during the past ASCO meetings amounts to only one-eighth of the number of abstracts on NSCLC. Some specific reasons may be responsible for the decrease in applied research in SCLC. The incidence of SCLC has dropped over the last decades mainly due to changes in smoking habits, whereas efforts to improve survival by means of systemic treatment have been stagnating for years. One of the rare appreciable improvements impacting survival of patients with ES-SCLC was made with prophylactic cranial irradiation (PCI) treatment. On the basis of recently published data, it seems that revisiting past experience with surgery in LS-SCLC may be one of the most promising perspectives to regain interest in tailored therapy in SCLC. In many malignancies targeted therapies have been successfully applied in the meantime. Developments in targeted therapy aiming at SCLC are lagging far behind, for example NSCLC. None of the abstracts concerning SCLC presented at this year's ASCO showed an improvement in survival and even worse is that only one phase III trial was presented in the lung cancer session and this trial showed negative results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24(28): 4539–4544, 2006

    Article  PubMed  Google Scholar 

  • Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med, 341(7): 476–484, 1999

    Article  PubMed  CAS  Google Scholar 

  • Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med, 357(7): 664–672, 2007

    Article  PubMed  CAS  Google Scholar 

  • Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol, 28(15): 2598–2603, 2010

    Article  PubMed  Google Scholar 

  • Fox W, Scadding JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet, 2(7820): 63–65, 1973

    Article  PubMed  CAS  Google Scholar 

  • Mountain CF. Clinical biology of small cell carcinoma: relationship to surgical therapy. Semin Oncol, 5(3): 272–279, 1978

    PubMed  CAS  Google Scholar 

  • Vallieres E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol, 4(9): 1049–1059, 2009

    Article  PubMed  Google Scholar 

  • Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer, 116(5): 1350–1357, 2010

    Article  PubMed  Google Scholar 

  • Yu JB, Decker RH, Detterbeck FC, et al. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol, 5(2): 215–219, 2010

    Article  PubMed  Google Scholar 

  • Lad T, Piantadosi S, Thomas P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest, 106(6 Suppl): 320S–323S, 1994

    Article  PubMed  CAS  Google Scholar 

  • Koletsis EN, Prokakis C, Karanikolas M, et al. Current role of surgery in small cell lung carcinoma. J Cardiothorac Surg, 4: 30, 2009

    Article  PubMed  Google Scholar 

  • Kalemkerian GP, et al. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer.; v.1.2011 [updated v.1.2011; cited 07/25/2010]; Available from: http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf

  • Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med, 327(23): 1618–1624, 1992

    Article  PubMed  CAS  Google Scholar 

  • Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol, 10(6): 890–895, 1992

    PubMed  CAS  Google Scholar 

  • Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol, 20(14): 3054–3060, 2002

    Article  PubMed  CAS  Google Scholar 

  • Turrisi AT, 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med, 340(4): 265–271, 1999

    Article  PubMed  CAS  Google Scholar 

  • van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys, 77(2): 329–336, 2010

    Article  PubMed  Google Scholar 

  • Le Pechoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol, 10(5): 467–474, 2009

    Article  PubMed  Google Scholar 

  • Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol, 27(1): 78–84, 2009

    Article  PubMed  Google Scholar 

  • Leyvraz S, Pampallona S, Martinelli G, et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst, 100(8): 533–541, 2008

    Article  PubMed  CAS  Google Scholar 

  • Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med, 346(2): 85–91, 2002

    Article  PubMed  CAS  Google Scholar 

  • Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol, 27(15): 2530–2535, 2009

    Article  PubMed  CAS  Google Scholar 

  • Zatloukal P, Cardenal F, Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol, 21(9): 1810–1816, 2010

    Article  PubMed  CAS  Google Scholar 

  • von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 17(2): 658–667, 1999

    PubMed  CAS  Google Scholar 

  • Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol, 25(15): 2086–2092, 2007

    Article  PubMed  CAS  Google Scholar 

  • Ciuleanu T, Samarzjia M, Demidchik Y, et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. J Clin Oncol, 28: 15s, 2010 (suppl; abstr 7002)

    Google Scholar 

  • Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol, 28(1): 43–48

Download references

Author information

Authors and Affiliations

  1. Division of Internal Medicine, Department of Oncology, Medical University of Graz, Graz, Austria

    F. Ploner

Authors
  1. F. Ploner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Ploner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ploner, F. SCLC – The forgotten entity. memo 4, 28–30 (2011). https://doi.org/10.1007/s12254-011-0240-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-011-0240-0

Keywords

Search

Navigation